The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences

GEO-CM04S1 Demonstrates Promise Among Most Vulnerable Immunocompromised Patients

6th ESCMID Conference on Vaccines: From Development to Real-World Clinical Practice and Global Health - September 10-13, 2025; Lisbon, Portugal
Presenter: Kelly T. McKee, Jr., MD, MPH; Chief Medical Officer, GeoVax Labs, Atlanta, Georgia
Format: Poster presentation (Poster: P060)
Session Details: Friday, September 12, 2025, Lisbon, Portugal
Topic: GEO-CM04S1, a multi-antigen COVID-19 vaccine for immunocompromised individuals: clinical evaluation to date.

For more information on the conference, please visit https://www.escmid.org/congress-events/6th-escmid-conference-on-vaccines.

International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025) – September 12–15, 2025; Krakow, Poland
Presenter: Alexey V. Danilov, MD, PhD; Professor, Department of Hematology and Transplantation; City of Hope National Medical Center, Duarte, California
Format: Poster presentation (Poster: 1717)
Session Details: Monday, September 15, 2025, from 08:15 to 09:40 CEST at the ICE Auditorium Hall (S1), Levels 0 & 1
Topic: MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia (CLL) compared with mRNA-based vaccine: initial results from a Phase II randomized study.

For more information on the conference, please visit https://www.iwcll.org/events/xxi-iwcll-12-15-september-2025-krakow-poland/

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com

Company Contact:
info@geovax.com
678-384-7220

Media Contact:
Jessica Starman
media@geovax.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.